SparingVision to Highlight Progress of its Lead Gene Therapy Program SPVN06 and Research on Retinitis Pigmentosa at ARVO 2022

SparingVision to Highlight Progress of its Lead Gene Therapy Program SPVN06 and Research on Retinitis Pigmentosa at ARVO 2022 Paris, March 31, 2022 – SparingVision (“the Company”), a genomic medicine company developing vision saving treatments for ocular diseases, announces today that it will be presenting data on its lead product candidate SPVN06 and the natural history of retinitis pigmentosa, its core focus indication, at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting to be held from 1-4 May. SparingVision have been selected for an oral presentation and for two poster presentations. Details can be found below: Oral Presentation: Prospective natural history of retinitis pigmentosa due to RHO, PDE6A, or PDE6B mutations: interim analysis of the PHENOROD2 study Date and Time: May 4, 2022 from 3:51 PM to 4:08 PM MDT, Presentation #4294 Presenter: Anne Celle Session Title: Retinal Degeneration Room: 205/207 (Denver Convention Center) Poster Presentation: Retrospective natural history of retinitis pigmentosa due to RHO, PDE6A, or PDE6B mutations: the PHENOROD1 study Date and Time: May 4, 2022 from 3:00 PM to 5:00 PM MDT, Poster #4497 – F0284 Presenter: Alice Le Meur Session Title: Retinal Degenerations, Gene Therapy, Transplantation, and Prostheses Poster Presentation: SPVN06, a novel mutation-independent AAV-based gene therapy, dramatically reduces vision loss in the rd10 mouse model of rod-cone dystrophy Date and Time: May 1, 2022 from 12:15 PM to 2:15 PM MDT, Poster #56 – A0029 Presenter: Dr. Florence Lorget, PharmD, PhD, DABT Session Title: Gene Therapy and Gene Editing for Ocular Disorders **ENDS**

The release as fetched from its publisher. sparingvision.com ↗